Dyne Therapeutics Stock Rises Amid $14 Million Stake Reduction by FCPM III Services B.V.

On May 15, 2026, FCPM III Services B.V. sold approximately $14 million worth of Dyne Therapeutics shares (NASDAQ:DYN), reducing its stake in the biotech firm. Despite this sell-off, Dyne's stock has risen by 56% year-to-date and is now valued at $18.28 per share as of May 14.

By Jonathan Ponciano, The Motley Fool Sat, May 30, 2026 at 7:48 PM GMT+3 4 min read · Yahoo Finance · May 30, 2026, 16:48 UTC

Tickers: $DYN $NAMS $VOR

Topics: Dyne Therapeutics FCPM III Services B.V. SEC filing selling activity

Read the full article at Yahoo Finance

More World news

Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC